You can seek FDA approval to launch a generic drug before the expiration of BELVIQ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BELVIQ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BELVIQ:-

You can seek FDA approval to launch a generic drug before the expiration of BELVIQ XR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BELVIQ XR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BELVIQ XR:-

You can seek FDA approval to launch a generic drug before the expiration of COMPLERA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the COMPLERA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on COMPLERA:-

You can seek FDA approval to launch a generic drug before the expiration of COREG CR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the COREG CR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on COREG CR:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of DEXILANT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the DEXILANT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on DEXILANT:-

You can seek FDA approval to launch a generic drug before the expiration of DIFICID's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the DIFICID's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on DIFICID:-

You can seek FDA approval to launch a generic drug before the expiration of FERAHEME's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the FERAHEME's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on FERAHEME:-

You can seek FDA approval to launch a generic drug before the expiration of HALAVEN's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the HALAVEN's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on HALAVEN:-

You can seek FDA approval to launch a generic drug before the expiration of IBRANCE's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the IBRANCE's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on IBRANCE:-

You can seek FDA approval to launch a generic drug before the expiration of INJECTAFER's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the INJECTAFER's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on INJECTAFER:-

You can seek FDA approval to launch a generic drug before the expiration of ISENTRESS's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ISENTRESS's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ISENTRESS:-

You can seek FDA approval to launch a generic drug before the expiration of ISENTRESS HD's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ISENTRESS HD's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ISENTRESS HD:-

You can seek FDA approval to launch a generic drug before the expiration of JULUCA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the JULUCA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on JULUCA:-

You can seek FDA approval to launch a generic drug before the expiration of KOMBIGLYZE XR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the KOMBIGLYZE XR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on KOMBIGLYZE XR:-

You can seek FDA approval to launch a generic drug before the expiration of LATISSE's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the LATISSE's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on LATISSE:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of MEKTOVI's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the MEKTOVI's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on MEKTOVI:-

You can seek FDA approval to launch a generic drug before the expiration of MYRBETRIQ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the MYRBETRIQ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on MYRBETRIQ:-

You can seek FDA approval to launch a generic drug before the expiration of NUVIGIL's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the NUVIGIL's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on NUVIGIL:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of ODEFSEY's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ODEFSEY's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ODEFSEY:-

You can seek FDA approval to launch a generic drug before the expiration of ONGLYZA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ONGLYZA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ONGLYZA:-

You can seek FDA approval to launch a generic drug before the expiration of OTEZLA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the OTEZLA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on OTEZLA:-

You can seek FDA approval to launch a generic drug before the expiration of PRESTALIA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the PRESTALIA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on PRESTALIA:-

You can seek FDA approval to launch a generic drug before the expiration of QTERN's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the QTERN's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on QTERN:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of TASIGNA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the TASIGNA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on TASIGNA:-

You can seek FDA approval to launch a generic drug before the expiration of VYVANSE's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the VYVANSE's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on VYVANSE:-

You can seek FDA approval to launch a generic drug before the expiration of XELJANZ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the XELJANZ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on XELJANZ:-